TY - JOUR
T1 - Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology
AU - Moura, B.
AU - Aimo, A.
AU - Al-Mohammad, A.
AU - Flammer, A.
AU - Barberis, V.
AU - Bayes-Genis, A.
AU - Brunner-La Rocca, H.P.
AU - Fontes-Carvalho, R.
AU - Grapsa, J.
AU - Hulsmann, M.
AU - Ibrahim, N.
AU - Knackstedt, C.
AU - Januzzi, J.L.
AU - Lapinskas, T.
AU - Sarrias, A.
AU - Matskeplishvili, S.
AU - Meijers, W.C.
AU - Messroghli, D.
AU - Mueller, C.
AU - Pavo, N.
AU - Teske, A.J.
AU - Kimmenade, R.
AU - Seferovic, P.
AU - Coats, A.J.S.
AU - Emdin, M.
AU - Richards, A.M.
PY - 2021/10
Y1 - 2021/10
N2 - Circulating biomarkers and imaging techniques provide independent and complementary information to guide management of heart failure (HF). This consensus document by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) presents current evidence-based indications relevant to integration of imaging techniques and biomarkers in HF. The document first focuses on application of circulating biomarkers together with imaging findings, in the broad domains of screening, diagnosis, risk stratification, guidance of treatment and monitoring, and then discusses specific challenging settings. In each section we crystallize clinically relevant recommendations and identify directions for future research. The target readership of this document includes cardiologists, internal medicine specialists and other clinicians dealing with HF patients.
AB - Circulating biomarkers and imaging techniques provide independent and complementary information to guide management of heart failure (HF). This consensus document by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) presents current evidence-based indications relevant to integration of imaging techniques and biomarkers in HF. The document first focuses on application of circulating biomarkers together with imaging findings, in the broad domains of screening, diagnosis, risk stratification, guidance of treatment and monitoring, and then discusses specific challenging settings. In each section we crystallize clinically relevant recommendations and identify directions for future research. The target readership of this document includes cardiologists, internal medicine specialists and other clinicians dealing with HF patients.
KW - Biomarkers
KW - Imaging
KW - Diagnosis
KW - Management
KW - Heart failure
KW - Consensus document
KW - PRESERVED EJECTION FRACTION
KW - BRAIN NATRIURETIC PEPTIDE
KW - SPECKLE-TRACKING ECHOCARDIOGRAPHY
KW - CARDIOVASCULAR MAGNETIC-RESONANCE
KW - DIFFUSE MYOCARDIAL FIBROSIS
KW - LATE GADOLINIUM ENHANCEMENT
KW - WORSENING RENAL-FUNCTION
KW - INDIVIDUAL PATIENT DATA
KW - 2013 ACCF/AHA GUIDELINE
KW - SUDDEN CARDIAC DEATH
U2 - 10.1002/ejhf.2339
DO - 10.1002/ejhf.2339
M3 - Article
SN - 1388-9842
VL - 23
SP - 1577
EP - 1596
JO - European journal of heart failure
JF - European journal of heart failure
IS - 10
ER -